In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals

PurposeThe application of in vivo bioluminescence imaging to non-invasive, quantitative monitoring of tumour models relies on a positive correlation between the intensity of bioluminescence and the tumour burden. We conducted cell culture studies to investigate the relationship between bioluminescent signal intensity and viable cell numbers in murine leukaemia model cells.MethodsInterleukin-3 (IL-3)-dependent murine pro-B cell line Ba/F3 was transduced with firefly luciferase to generate cells expressing luciferase stably under the control of a retroviral long terminal repeat. The luciferase-expressing cells were transduced with p190 BCR-ABL to give factor-independent proliferation. The cells were cultured under various conditions, and bioluminescent signal intensity was compared with viable cell numbers and the cell cycle stage.ResultsThe Ba/F3 cells showed autonomous growth as well as stable luciferase expression following transduction with both luciferase and p190 BCR-ABL, and in vivo bioluminescence imaging permitted external detection of these cells implanted into mice. The bioluminescence intensities tended to reflect cell proliferation and responses to imatinib in cell culture studies. However, the luminescence per viable cell was influenced by the IL-3 concentration in factor-dependent cells and by the stage of proliferation and imatinib concentration in factor-independent cells, thereby impairing the proportionality between viable cell number and bioluminescent signal intensity. Luminescence per cell tended to vary in association with the fraction of proliferating cells.ConclusionAlthough in vivo bioluminescence imaging would allow non-invasive monitoring of leukaemia model animals, environmental factors and therapeutic interventions may cause some discrepancies between tumour burden and bioluminescence intensity.

[1]  G. Splitter,et al.  Bovine Herpesvirus Tegument Protein VP22 Enhances Thymidine Kinase/Ganciclovir Suicide Gene Therapy for Neuroblastomas Compared to Herpes Simplex Virus VP22 , 2004, Journal of Virology.

[2]  Ralph Weissleder,et al.  In vivo tracking of neural progenitor cell migration to glioblastomas. , 2003, Human gene therapy.

[3]  Ralph Weissleder,et al.  Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo , 2003, Oncogene.

[4]  Peter P. Antich,et al.  Validating Bioluminescence Imaging as a High-Throughput, Quantitative Modality for Assessing Tumor Burden , 2004 .

[5]  C. Contag,et al.  Visualizing the kinetics of tumor-cell clearance in living animals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[7]  C. Contag,et al.  Use of reporter genes for optical measurements of neoplastic disease in vivo. , 2000, Neoplasia.

[8]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[9]  S. Y. Lee,et al.  Cell uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase based gene imaging , 2003, Nuclear medicine communications.

[10]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[11]  T. Kitamura,et al.  Plat-E: an efficient and stable system for transient packaging of retroviruses , 2000, Gene Therapy.

[12]  K. Wood,et al.  Photographic detection of luminescence in Escherichia coli containing the gene for firefly luciferase. , 1987, Analytical biochemistry.

[13]  M. Steinmetz,et al.  IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivo , 1985, Cell.

[14]  Ralph Weissleder,et al.  Glioma therapy and real‐time imaging of neural precursor cell migration and tumor regression , 2005, Annals of neurology.

[15]  I. B. Borel Rinkes,et al.  Validation of bioluminescence imaging of colorectal liver metastases in the mouse. , 2004, The Journal of surgical research.

[16]  C. Contag,et al.  Advancing animal models of neoplasia through in vivo bioluminescence imaging. , 2002, European journal of cancer.

[17]  G. Brightwell,et al.  Serum-dependent and cell cycle-dependent expression from a cytomegalovirus-based mammalian expression vector. , 1997, Gene.

[18]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Kitamura,et al.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. , 2003, Experimental hematology.

[20]  M. Santoro,et al.  Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells , 2003, Oncogene.

[21]  M. Dewhirst,et al.  Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. , 2004, The Journal of surgical research.

[22]  S. Gambhir,et al.  Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. , 2004, Human gene therapy.

[23]  M Aizawa,et al.  Biosensing of benzene derivatives in the environment by luminescent Escherichia coli. , 1995, Biosensors & bioelectronics.

[24]  E. Copelan,et al.  The biology and treatment of acute lymphoblastic leukemia in adults. , 1995, Blood.

[25]  F. Blankenberg,et al.  Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. , 2004, Molecular imaging.

[26]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[27]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[28]  C. Scatena,et al.  Imaging of bioluminescent LNCaP‐luc‐M6 Tumors: A new animal model for the study of metastatic human prostate cancer , 2004, The Prostate.

[29]  Peter Choyke,et al.  Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. , 2003, BioTechniques.

[30]  F. Salvatore,et al.  BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations , 2002, Oncogene.

[31]  P. Andreotti,et al.  Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors , 2003, Anti-cancer drugs.

[32]  S. Kimura,et al.  Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. , 2005, Cancer letters.

[33]  Jos Jonkers,et al.  Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. , 2002, Cancer research.

[34]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[35]  D. Jenkins,et al.  Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis , 2004, Clinical & Experimental Metastasis.

[36]  N. Rubio,et al.  Combined Noninvasive Imaging and Luminometric Quantification of Luciferase-Labeled Human Prostate Tumors and Metastases , 2002, Laboratory Investigation.

[37]  Christopher H Contag,et al.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. , 2003, Blood.

[38]  Z Symon,et al.  The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model , 2002, Gene Therapy.

[39]  T. Lipp,et al.  Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.

[40]  C. Peschel,et al.  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.